Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 37, 2011, Pages 15336-15341

  Aung, Thiha ^a   Chapuy, Bjoern ^a,b   Vogel, Daniel ^a   Wenzel, Dirk ^c   Oppermann, Martin ^a   Lahmann, Marlen ^a   Weinhage, Toni ^a   Menck, Kerstin ^a   Hupfeld, Timo ^a   Koch, Raphael ^a   Trümper, Lorenz ^a   Wulf, Gerald G ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ATP BINDING CASSETTE TRANSPORTER A3; CD20 ANTIBODY; CD20 ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; BIOGENESIS; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; EXOSOME; GENE SILENCING; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNOMODULATION; LYMPHOMA CELL; LYSOSOME; PRIORITY JOURNAL; TARGET CELL;

ABSORPTION; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEOPLASM; ANTIGENS, CD20; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; EXOSOMES; GENE SILENCING; HUMANS; IMMUNE EVASION; IMMUNITY, HUMORAL; IMMUNOTHERAPY; LYMPHOMA, B-CELL;

EID: 80053067140     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1102855108     Document Type: Article

References (55)

1. Maloney DG, et al. (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466. (Pubitemid 24317376)
2. McLaughlin P (1999) Treatment of follicular and other indolent lymphomas. Curr Opin Oncol 11:333-338.
3. Coiffier B, et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242. (Pubitemid 34438862)
4. Keating GM (2010) Rituximab: A review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70: 1445-1476.
5. Gisselbrecht C (2008) Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haematol 143:607-621.
6. Manches O, et al. (2003) In vitro mechanisms of action of rituximab on primary non- Hodgkin lymphomas. Blood 101:949-954. (Pubitemid 36139365)
7. Théry C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9:581-593.
8. Trams EG, Lauter CJ, Salem N, Jr., Heine U (1981) Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. Biochim Biophys Acta 645:63-70.
9. Harding C, Heuser J, Stahl P (1983) Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 97:329-339.
10. Pan BT, Teng K, Wu C, Adam M, Johnstone RM (1985) Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol 101:942-948. (Pubitemid 16256847)
11. Raposo G, et al. (1996) B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183:1161-1172. (Pubitemid 26113979)
12. Zitvogel L, et al. (1998) Eradication of established murine tumors using a novel cellfree vaccine: Dendritic cell-derived exosomes. Nat Med 4:594-600. (Pubitemid 28237359)
13. Escudier B, et al. (2005) Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of the first phase I clinical trial. J Transl Med 3:10.
14. Bard MP, et al. (2004) Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol 31:114-121. (Pubitemid 38888047)
15. Savina A, Fader CM, Damiani MT, Colombo MI (2005) Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic 6:131-143.
16. Chapuy B, et al. (2008) Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia 22:1576-1586.
17. Steinbach D, et al. (2006) ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 12:4357-4363.
18. Chapuy B, et al. (2009) ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. Haematologica 94:1528-1536.
19. Théry C, Zitvogel L, Amigorena S (2002) Exosomes: Composition, biogenesis and function. Nat Rev Immunol 2:569-579. (Pubitemid 37328732)
20. Cragg MS, et al. (2004) A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood 104:2540-2542. (Pubitemid 39331858)
21. Hampson G, et al. (2010) Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. J Immunol Methods 360:30-38.
22. Rabesandratana H, Toutant JP, Reggio H, Vidal M (1998) Decay-accelerating factor (CD55) and membrane inhibitor of reactive lysis (CD59) are released within exosomes during in vitro maturation of reticulocytes. Blood 91:2573-2580. (Pubitemid 28155534)
23. Clayton A, Harris CL, Court J, Mason MD, Morgan BP (2003) Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. Eur J Immunol 33:522-531. (Pubitemid 36267618)
24. Pilzer D, Gasser O, Moskovich O, Schifferli JA, Fishelson Z (2005) Emission of membrane vesicles: Roles in complement resistance, immunity and cancer. Springer Semin Immunopathol 27:375-387. (Pubitemid 41639888)
25. Fader CM, Sánchez D, Furlán M, Colombo MI (2008) Induction of autophagy promotes fusion of multivesicular bodies with autophagic vacuoles in k562 cells. Traffic 9: 230-250.
26. Chalmin F, et al. (2010) Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid- derived suppressor cells. J Clin Invest 120:457-471.
27. Strauss K, et al. (2010) Exosome secretion ameliorates lysosomal storage of cholesterol in Niemann-Pick type C disease. J Biol Chem 285:26279-26288.
28. Song JH, Kim SH, Kim HJ, Hwang SY, Kim TS (2008) Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin. Int J Oncol 32:931-936. (Pubitemid 351780604)
29. Anderson KC, et al. (1984) Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63:1424-1433. (Pubitemid 14120390)
30. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7:711-717.
31. Reiser M, et al. (2006) Serum levels and pharmacokinetic of rituximab in bi-weekly RCHOP in elderly patients with DLBCL treated in the RICOVER-60 trial. Blood 108:2748.
32. Press OW, et al. (1987) Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584-591. (Pubitemid 17022032)
33. Hakulinen J, Junnikkala S, Sorsa T, Meri S (2004) Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form. Eur J Immunol 34:2620-2629. (Pubitemid 39302819)
34. Yamano G, et al. (2001) ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells. FEBS Lett 508:221-225. (Pubitemid 33079249)
35. Mulugeta S, et al. (2002) Identification of LBM180, a lamellar body limiting membrane protein of alveolar type II cells, as the ABC transporter protein ABCA3. J Biol Chem 277:22147-22155. (Pubitemid 34967179)
36. Matsumura Y, Sakai H, Sasaki M, Ban N, Inagaki N (2007) ABCA3-mediated cholinephospholipids uptake into intracellular vesicles in A549 cells. FEBS Lett 581:3139-3144. (Pubitemid 46977352)
37. Wenzel JJ, Piehler A, Kaminski WE (2007) ABC A-subclass proteins: Gatekeepers of cellular phospho- and sphingolipid transport. Front Biosci 12:3177-3193.
38. Ban N, et al. (2007) ABCA3 as a lipid transporter in pulmonary surfactant biogenesis. J Biol Chem 282:9628-9634. (Pubitemid 47104606)
39. Cheong N, et al. (2007) ABCA3 is critical for lamellar body biogenesis in vivo. J Biol Chem 282:23811-23817. (Pubitemid 47328028)
40. Efferth T, et al. (2006) Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther 5:1986-1994. (Pubitemid 44336570)
41. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427. (Pubitemid 23237876)
42. Hedley DW, et al. (1997) A novel energy dependent mechanism reducing daunorubicin accumulation in acute myeloid leukemia. Leukemia 11:48-53. (Pubitemid 27065049)
43. Hirschmann-Jax C, et al. (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101:14228-14233. (Pubitemid 39305058)
44. Yasui K, et al. (2004) Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 64:1403-1410. (Pubitemid 38235609)
45. Yang X, Liu Y, Zong Z, Tian D (2010) The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells. Biomed Pharmacother 64:58-62.
46. Schimanski S, et al. (2010) Expression of the lipid transporters ABCA3 and ABCA1 is diminished in human breast cancer tissue. Horm Metab Res 42:102-109.
47. Wanner K, et al. (2006) Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134:475-484. (Pubitemid 44141713)
48. HullMA, Gardner SH, Hawcroft G (2003) Activity of the non-steroidal anti-inflammatory drug indomethacin against colorectal cancer. Cancer Treat Rev 29:309-320. (Pubitemid 37069661)
49. André F, et al. (2002) Tumor-derived exosomes: A new source of tumor rejection antigens. Vaccine 20(Suppl 4):A28-A31. (Pubitemid 35452633)
50. Février B, Raposo G (2004) Exosomes: Endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 16:415-421. (Pubitemid 38903148)
51. Van Niel G, Porto-Carreiro I, Simoes S, Raposo G (2006) Exosomes: A common pathway for a specialized function. J Biochem 140:13-21. (Pubitemid 44433541)
52. Riteau B, et al. (2003) Exosomes bearing HLA-G are released by melanoma cells. Hum Immunol 64:1064-1072. (Pubitemid 37413716)
53. Taylor DD, Gerçel-Taylor C (2005) Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 92:305-311. (Pubitemid 40343146)
54. Johnson NA, et al. (2009) Diffuse large B-cell lymphoma: Reduced CD20 expression is associated with an inferior survival. Blood 113:3773-3780.
55. Valadi H, et al. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654-659. (Pubitemid 47214727)